Literature DB >> 30794777

SnapShot: Cancer Immunotherapy with Oncolytic Viruses.

Shashi Gujar1, John Bell2, Jean-Simon Diallo2.   

Abstract

Oncolytic viruses (OVs) preferentially infect and kill cancer cells without harming normal cells. OVs can revert cancer-associated immune suppression and initiate clinically meaningful antitumor immune responses. OVs and their resultant immunological events can act at both primary and metastatic sites. Thus, OVs can be exploited for cancer gene therapies and immunotherapies alone or in combination with other interventions, including immune checkpoint blockade.
Copyright © 2019. Published by Elsevier Inc.

Entities:  

Year:  2019        PMID： 30794777     DOI： 10.1016/j.cell.2019.01.051

Source DB:  PubMed          Journal:  Cell        ISSN： 0092-8674            Impact factor:   41.582


  18 in total

Review 1.  Next-generation stem cells - ushering in a new era of cell-based therapies.

Authors:  Erin A Kimbrel; Robert Lanza
Journal:  Nat Rev Drug Discov       Date:  2020-04-06       Impact factor: 84.694

Review 2.  Advances in the clinical development of oncolytic viruses.

Authors:  Ke Li; Yalong Zhao; Xiaocong Hu; Jiao Jiao; Wei Wang; Hongtao Yao
Journal:  Am J Transl Res       Date:  2022-06-15       Impact factor: 3.940

Review 3.  Oncolytic virotherapy reverses the immunosuppressive tumor microenvironment and its potential in combination with immunotherapy.

Authors:  Yalei Zhang; Ye Li; Kun Chen; Ling Qian; Peng Wang
Journal:  Cancer Cell Int       Date:  2021-05-13       Impact factor: 5.722

4.  In Situ Therapeutic Cancer Vaccination with an Oncolytic Virus Expressing Membrane-Tethered IL-2.

Authors:  Weilin Liu; Enyong Dai; Zuqiang Liu; Congrong Ma; Zong Sheng Guo; David L Bartlett
Journal:  Mol Ther Oncolytics       Date:  2020-04-21       Impact factor: 7.200

5.  The strategic combination of trastuzumab emtansine with oncolytic rhabdoviruses leads to therapeutic synergy.

Authors:  Rozanne Arulanandam; Zaid Taha; Vanessa Garcia; Mohammed Selman; Andrew Chen; Oliver Varette; Anna Jirovec; Keara Sutherland; Elizabeth Macdonald; Fanny Tzelepis; Harsimrat Birdi; Nouf Alluqmani; Anne Landry; Anabel Bergeron; Barbara Vanderhyden; Jean-Simon Diallo
Journal:  Commun Biol       Date:  2020-05-22

Review 6.  Innate Immune Cells: A Potential and Promising Cell Population for Treating Osteosarcoma.

Authors:  Zenan Wang; Zhan Wang; Binghao Li; Shengdong Wang; Tao Chen; Zhaoming Ye
Journal:  Front Immunol       Date:  2019-05-16       Impact factor: 7.561

Review 7.  Role of Myeloid Cells in Oncolytic Reovirus-Based Cancer Therapy.

Authors:  Vishnupriyan Kumar; Michael A Giacomantonio; Shashi Gujar
Journal:  Viruses       Date:  2021-04-10       Impact factor: 5.048

Review 8.  Repurposing CD8+ T cell immunity against SARS-CoV-2 for cancer immunotherapy: a positive aspect of the COVID-19 pandemic?

Authors:  Shashi Gujar; Jonathan G Pol; Youra Kim; Guido Kroemer
Journal:  Oncoimmunology       Date:  2020-07-16       Impact factor: 8.110

9.  Oncolytic poxvirus CF33-hNIS-ΔF14.5 favorably modulates tumor immune microenvironment and works synergistically with anti-PD-L1 antibody in a triple-negative breast cancer model.

Authors:  Shyambabu Chaurasiya; Annie Yang; Seonah Kang; Jianming Lu; Sang-In Kim; Anthony K Park; Venkatesh Sivanandam; Zhifang Zhang; Yanghee Woo; Susanne G Warner; Yuman Fong
Journal:  Oncoimmunology       Date:  2020-02-24       Impact factor: 8.110

Review 10.  Oncolytic Viruses as a Platform for the Treatment of Malignant Brain Tumors.

Authors:  Jana de Sostoa; Valérie Dutoit; Denis Migliorini
Journal:  Int J Mol Sci       Date:  2020-10-09       Impact factor: 5.923
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.